Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi

Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems. Individuals may be co-infected, raising the possibility of important interactions between these two pathogens with consequences for LF elimination through annual mass drug administration (MDA). We anal...

Full description

Saved in:

Bibliographic Details
Published in:	PLoS neglected tropical diseases 2015-06, Vol.9 (6), p.e0003825
Main Authors:	Tafatatha, Terence, Taegtmeyer, Miriam, Ngwira, Bagrey, Phiri, Amos, Kondowe, Mariot, Piston, Wilson, Molesworth, Anna, Kayuni, Ndoliwe, Koole, Olivier, Crampin, Amelia, Horton, John, French, Neil
Format:	Article
Language:	eng
Subjects:	Adult Anti-Retroviral Agents - therapeutic use Antigens Antigens, Helminth - blood Coinfection - epidemiology Cross-Sectional Studies Drug therapy Elephantiasis, Filarial - epidemiology Funding HIV HIV Infections - drug therapy HIV Infections - epidemiology Human immunodeficiency virus Humans Infections Information sharing Malawi - epidemiology Population Prevalence Public health Rural Population - statistics & numerical data Studies Time Factors Tropical diseases
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems. Individuals may be co-infected, raising the possibility of important interactions between these two pathogens with consequences for LF elimination through annual mass drug administration (MDA). We analysed circulating filarial antigenaemia (CFA) by HIV infection status among adults in two sites in northern Malawi, a region endemic for both LF and HIV. Stored blood samples and data from two geographically separate studies were used: one a recruitment phase of a clinical trial of anti-filarial agent dosing regimens, and the other a whole population annual HIV sero-survey. In study one, 1,851 consecutive adult volunteers were screened for HIV and LF infection. CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/1487) in HIV-negative participants (p=0.57). Geometric mean CFA concentrations were 859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio (GMR) 0.85, 95%CI 0.49-1.50. In 7,863 adults in study two, CFA prevalence was 20.9% (86/411) in HIV-positive and 24.0% (1789/7452) in HIV-negative participants (p=0.15). Geometric mean CFA concentrations were 630 and 839 Ag/ml respectively (GMR 0.75, 95%CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associated with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95%CI 0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59), 13.6% >1-2 years (n=44), 10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9), p
ISSN:	1935-2735 1935-2727 1935-2735